JnJ closes Intra-Cellular Therapies acquisition Ruchika Sharma3 April 2025 10:30 AM ISTNew Brunswick: Johnson & Johnson has announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is...
JnJ to acquire Intra-Cellular Therapies for USD 14.6 billion Ruchika Sharma15 Jan 2025 11:30 AM ISTNew Brunswick: Johnson & Johnson and Intra-Cellular Therapies, Inc. have announced that they have entered into a definitive agreement under...
IQVIA Gets CDSCO Panel Nod To conduct Phase III clinical Study of Lumateperone Dr. Divya Colin28 Dec 2024 6:30 PM ISTNew Delhi: IQVIA has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to...
IQVIA Gets CDSCO Panel Nod to Study Antipsychotic drug Lumateperone Dr. Divya Colin17 Nov 2024 5:45 PM ISTNew Delhi: IQVIA has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to...
Sun Pharma Laboratories Gets CDSCO Panel Nod To Manufacture Market Antipsychotic Lumateperone Capsule Dr. Divya Colin17 Nov 2024 5:00 PM ISTNew Delhi: The pharmaceutical major Sun Pharma Laboratories has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central...
Lumateperone as adjunct significantly reduces depression symptoms in patients with major depressive disorder phase 3 trial shows Dr. Kamal Kant Kohli24 Jun 2024 8:30 PM ISTIntra-Cellular Therapies, Inc, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system...
Lumateperone promising for treatment of bipolar depression Dr. Kamal Kant Kohli18 July 2023 11:15 AM ISTCanada: Lumateperone could be a promising new treatment for major depressive episodes (MDEs) associated with bipolar I or bipolar II disorder in...
Sun Pharma gets CDSCO Panel nod to study Lumateperone Capsules Dr. Divya Colin29 Jun 2023 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) has granted permission to drug major...
Lumateperone safe and effective for major depressive episodes in bipolar patients: Study MD Editorial Team11 Oct 2021 9:00 AM ISTUSA: Lumateperone at 42 mg/day considerably reduced depression symptoms and was usually well tolerated in patients with major depressive episodes...
Lumateperone effective and safe treatment option in schizophrenia: JAMA Medha Baranwal20 Jan 2020 11:18 AM ISTUSA: Lumateperone is a potential treatment for schizophrenia and has a favorable safety profile, according to a recent study published in the journal...
